Important Safety Information | Prescribing Information

                  WHY CHOOSE PROLENSA

  • Advanced formulation delivers corneal penetration1,2
  • Proven efficacy at a low concentration

  • >2x as many patients had complete clearance of inflammation vs vehicle at Day 151,8
  • ~4 of 5 patients were pain free at Day 11,8,*
  • Rapid reduction of inflammation at Days 8 and 159

*Ocular pain was evaluated by the Ocular Comfort Grading Assessment.

  • Ocular comfort and QD dosing1,7
       ›› Patients reported less foreign body sensation and photophobia and had less            redness vs vehicle7
  • Close to the physiological pH of natural tears1,6

  • For more than 10 years, Bausch + Lomb has been a leader in the evolution of ophthalmic NSAIDs with a molecule designed to help treat post-cataract inflammation and pain
  • Approved by the FDA in 2013 with a documented efficacy and safety profile1
  • A sterile formulation manufactured in an FDA-approved facility
  • No generic equivalent available

Download this helpful fact sheet to keep PROLENSA clinical and patient savings program
information easily accessible in your practice.


PROLENSA (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.


  • PROLENSA contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

  • All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

  • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs.

  • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.

  • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.

  • PROLENSA should not be instilled while wearing contact lenses. The preservative in PROLENSA, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA.

  • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.

Please click here for Prescribing Information about PROLENSA.
Please click here for references.